Literature DB >> 23987199

Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence.

Karen E Wells1, Edward L Peterson, Brian K Ahmedani, L Keoki Williams.   

Abstract

BACKGROUND: Nonadherence to inhaled corticosteroids (ICSs) for asthma maintenance therapy is common and is associated with poor asthma outcomes. Simplifying dosing regimens for some chronic disease conditions has resulted in better adherence; however, little is known regarding the effect of ICS dosing on adherence for the treatment of asthma.
OBJECTIVE: To determine whether once daily dosing is associated with higher adherence to ICS therapy when compared with 2 or more times daily dosing among patients with asthma.
METHODS: Six years of pharmacy claims data were linked with prescription information to estimate ICS therapy adherence for patients with asthma 12 to 56 years of age who were members of a large health maintenance organization. Patient follow-up continued from the initial ICS fill until one of the following: the last ICS fill in the observation period, a switch of ICS dosing regimen, or the initiation of ICS and long-acting β-agonist combination therapy. Adherence was estimated by calculating a continuous multiple-interval measure of medication availability. Regression models were used to assess the relationship between adherence in patients treated with once daily vs 2 or more times daily ICS therapy.
RESULTS: Among the 1,302 patients who met the inclusion criteria, 17% were prescribed once daily therapy, and 83% were prescribed 2 or more times daily therapy. Models comparing ICS adherence among individuals following once daily and 2 or more times daily ICS regimens suggested that once daily dosing was associated with an approximately 20% increase in adherence. This significant difference persisted among subgroups defined by sex, race/ethnicity, age, and asthma severity.
CONCLUSION: Once daily dosing was associated with higher adherence to ICS therapy; this included clinically relevant subgroups.
Copyright © 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23987199      PMCID: PMC3763990          DOI: 10.1016/j.anai.2013.06.008

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  25 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence.

Authors:  L Keoki Williams; Edward L Peterson; Karen Wells; Brian K Ahmedani; Rajesh Kumar; Esteban G Burchard; Vimal K Chowdhry; David Favro; David E Lanfear; Manel Pladevall
Journal:  J Allergy Clin Immunol       Date:  2011-10-21       Impact factor: 10.793

3.  Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs.

Authors:  Julian F Guest; Alison M Davie; Francis J Ruiz; Mark J Greener
Journal:  Prim Care Respir J       Date:  2005-02-24

4.  Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients.

Authors:  Prakash Navaratnam; Howard S Friedman; Eduardo Urdaneta
Journal:  Value Health       Date:  2011 Mar-Apr       Impact factor: 5.725

5.  The impact of adherence and disease control on resource use and charges in patients with mild asthma managed on inhaled corticosteroid agents.

Authors:  P Navaratnam; H S Friedman; E Urdaneta
Journal:  Patient Prefer Adherence       Date:  2010-06-24       Impact factor: 2.711

6.  Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence.

Authors:  Faustinus Onyirimba; Andrea Apter; Susan Reisine; Mark Litt; Corliss McCusker; MaryLou Connors; Richard ZuWallack
Journal:  Ann Allergy Asthma Immunol       Date:  2003-04       Impact factor: 6.347

Review 7.  Adherence intervention research: what have we learned and what do we do next?

Authors:  Bruce Bender; Henry Milgrom; Andrea Apter
Journal:  J Allergy Clin Immunol       Date:  2003-09       Impact factor: 10.793

8.  The prevalence of nonadherence in difficult asthma.

Authors:  Jacqueline Gamble; Michael Stevenson; Elizabeth McClean; Liam G Heaney
Journal:  Am J Respir Crit Care Med       Date:  2009-07-30       Impact factor: 21.405

9.  Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma.

Authors:  Karen Wells; Manel Pladevall; Edward L Peterson; Janis Campbell; Mingqun Wang; David E Lanfear; L Keoki Williams
Journal:  Am J Respir Crit Care Med       Date:  2008-10-10       Impact factor: 21.405

Review 10.  Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings.

Authors:  K Schroeder; T Fahey; S Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2004
View more
  13 in total

1.  Patient and provider perspectives on uptake of a shared decision making intervention for asthma in primary care practices.

Authors:  Madelyn Welch; Thomas Ludden; Kathleen Mottus; Paul Bray; Lori Hendrickson; Jennifer Rees; Jacqueline Halladay; Hazel Tapp
Journal:  J Asthma       Date:  2018-06-21       Impact factor: 2.515

2.  Optimal cut-off value and clinical usefulness of the Adherence Starts with Knowledge-12 in patients with asthma taking inhaled corticosteroids.

Authors:  Masaya Takemura; Masayuki Nishio; Kensuke Fukumitsu; Norihisa Takeda; Hiroya Ichikawa; Takamitsu Asano; Hiroki Tomita; Yoshihiro Kanemitsu; Kosho Yoshikawa; Akio Niimi
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

3.  A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.

Authors:  Dave Singh; Helena Pujol; Anna Ribera; Beatriz Seoane; Eric Massana; Carol Astbury; Sandrine Ruiz; Gonzalo de Miquel
Journal:  BMC Pulm Med       Date:  2014-11-14       Impact factor: 3.317

Review 4.  The use of inhaled corticosteroids in pediatric asthma: update.

Authors:  Elham Hossny; Nelson Rosario; Bee Wah Lee; Meenu Singh; Dalia El-Ghoneimy; Jian Yi Soh; Peter Le Souef
Journal:  World Allergy Organ J       Date:  2016-08-12       Impact factor: 4.084

5.  Assessment of dog owner adherence to veterinarians' flea and tick prevention recommendations in the United States using a cross-sectional survey.

Authors:  Robert P Lavan; Kaan Tunceli; Dongmu Zhang; Dorothy Normile; Rob Armstrong
Journal:  Parasit Vectors       Date:  2017-06-06       Impact factor: 3.876

6.  Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication.

Authors:  Sarah Chapman; Peter Dale; Henrik Svedsater; Gillian Stynes; Nicola Vyas; David Price; Rob Horne
Journal:  NPJ Prim Care Respir Med       Date:  2017-11-14       Impact factor: 2.871

Review 7.  Severe asthma and quality of life.

Authors:  Elham Hossny; Luis Caraballo; Thomas Casale; Yehia El-Gamal; Lanny Rosenwasser
Journal:  World Allergy Organ J       Date:  2017-08-21       Impact factor: 4.084

Review 8.  Assessing asthma severity based on claims data: a systematic review.

Authors:  Christian Jacob; Jennifer S Haas; Benno Bechtel; Peter Kardos; Sebastian Braun
Journal:  Eur J Health Econ       Date:  2016-03-01

9.  Duration of annual canine flea and tick protection provided by dog owners in Spain.

Authors:  Robert Lavan; Rob Armstrong; Federica Burgio; Kaan Tunceli
Journal:  Parasit Vectors       Date:  2018-08-07       Impact factor: 3.876

10.  Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study).

Authors:  Yasuo Shimizu; Taichi Shiobara; Ryo Arai; Kazuyuki Chibana; Akihiro Takemasa
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.